EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction [0.03%]
EMPA-REGOUTCOME与心血管风险降低的长期管理：路漫漫其修远兮
Vanita R Aroda,Marc S Sabatine
Vanita R Aroda
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
Guideline recommendations and the positioning of newer drugs in type 2 diabetes care [0.03%]
二甲双胍在糖尿病治疗中的地位——基于指南的循证推荐
Nikolaus Marx,Melanie J Davies,Peter J Grant et al.
Nikolaus Marx et al.
Cardiovascular outcome trials in patients with type 2 diabetes at high cardiovascular risk have led to remarkable advances in our understanding of the effectiveness of GLP-1 receptor agonists and SGLT2 inhibitors to reduce cardiorenal event...
Ricardo V Cohen,Luciano F Drager,Tarissa B Z Petry et al.
Ricardo V Cohen et al.
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials [0.03%]
针对由于LEPR或POMC缺陷导致重度肥胖患者的司美泰肽（MC4受体激动剂）疗效和安全性：一项单臂、开放标签、多中心的三期临床试验
Karine Clément,Erica van den Akker,Jesús Argente et al.
Karine Clément et al.
Background: The melanocortin 4 receptor (MC4R), a component of the leptin-melanocortin pathway, plays a part in bodyweight regulation. Severe early-onset obesity can be caused by biallelic variants in genes that affect th...
Robert A Hegele,Grant M Maltman
Robert A Hegele
At 2:00 h on Oct 31, 1920, Frederick G Banting, a surgeon practising in London, ON, Canada, conceived an idea to isolate the internal secretion of the pancreas. The following week, he met with noted scientist John J R Macleod in Toronto, ON...
Catecholamine physiology and its implications in patients with COVID-19 [0.03%]
儿茶酚胺的生理作用及其对新型冠状病毒肺炎患者的治疗意义
Sriram Gubbi,Matthew A Nazari,David Taieb et al.
Sriram Gubbi et al.
The risk factors for severe COVID-19 are diverse, yet closely resemble the clinical manifestations of catecholamine excess states (eg, hypertension, cardiovascular disease, immune dysregulation, and hyperglycaemia), suggesting a potentially...